Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMNSJ3C)

Drug Name
JNJ-26854165 Drug Info
Synonyms
Serdemetan; 881202-45-5; N1-(2-(1H-Indol-3-yl)ethyl)-N4-(pyridin-4-yl)benzene-1,4-diamine; JNJ-26854165 (Serdemetan); UNII-ID6YB4W3V8; ID6YB4W3V8; C21H20N4; n-(2-(1h-indol-3-yl)ethyl)-n'-(4-pyridinyl)-1,4-benzenediamine; N-[2-(1H-INDOL-3-YL)ETHYL]-N'-(4-PYRIDINYL)-1,4-BENZENEDIAMINE; Serdemetan [INN]; MLS006011022; SCHEMBL3012498; CHEMBL2137530; CTK8C1936; EX-A267; DTXSID30236830; MolPort-009-679-468; HMS3654A16; JNJ 26854165 (Serdemetan); BCP02124; AOB87702; QC-534; ANW-67474
Cross-matching ID
PubChem CID
11609586
CAS Number
CAS 881202-45-5
TTD Drug ID
D0B3GF

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Steroid biosynthesis 2.65 0.00e+0 19/20 (95%) MSMO1;SQLE;SC5D;...
p53 signaling pathway 2.38 0.00e+0 63/73 (86.3%) CDKN1A;TNFRSF10B;SESN1;...
Terpenoid backbone biosynthesis 2.14 0.00e+0 18/22 (81.82%) HMGCS1;IDI1;FDPS;...
Influenza A 2.09 0.00e+0 156/172 (90.7%) FDPS;TNFRSF10B;TPSAB1;...
DNA replication 2.04 1.99e-3 34/36 (94.44%) PCNA;FEN1;MCM6;...
PPAR signaling pathway 1.94 6.64e-3 66/74 (89.19%) HMGCS1;SCD;FADS2;...
Graft-versus-host disease 1.91 5.69e-3 32/42 (76.19%) HLA-B;HLA-F;HLA-C;...
Small cell lung cancer 1.89 4.98e-3 90/92 (97.83%) CDKN1A;DDB2;CCND1;...
Biosynthesis of unsaturated fatty acids 1.87 5.54e-3 21/27 (77.78%) SCD;FADS1;FADS2;...
Viral protein interaction with cytokine and cytokine re... 1.86 6.98e-3 84/100 (84%) TNFRSF10B;CCL2;TNFRSF1A;...
Viral myocarditis 1.84 9.06e-3 53/60 (88.33%) HLA-B;CCND1;CXADR;...
Base excision repair 1.83 8.30e-3 29/33 (87.88%) PCNA;FEN1;LIG1;...
NF-kappa B signaling pathway 1.82 7.66e-3 90/104 (86.54%) PLAU;PTGS2;GADD45A;...
JAK-STAT signaling pathway 1.82 7.83e-3 146/162 (90.12%) CDKN1A;LIF;CCND1;...
Herpes simplex virus 1 infection 1.79 1.13e-2 165/498 (33.13%) CCL2;HLA-B;TAP1;...
Epstein-Barr virus infection 1.78 1.18e-2 189/202 (93.56%) CDKN1A;DDB2;HLA-B;...
Thyroid cancer 1.76 1.23e-2 36/37 (97.3%) CDKN1A;DDB2;CCND1;...
TNF signaling pathway 1.76 1.33e-2 103/112 (91.96%) CCL2;LIF;PTGS2;...
Hematopoietic cell lineage 1.73 2.10e-2 90/99 (90.91%) CD9;EPOR;HLA-DQA1;...
Synthesis and degradation of ketone bodies 1.72 2.04e-2 9/10 (90%) HMGCS1;ACAT2;BDH2
Basal cell carcinoma 1.71 2.33e-2 41/63 (65.08%) CDKN1A;DDB2;GADD45A;...
Allograft rejection 1.68 3.03e-2 32/38 (84.21%) HLA-B;HLA-F;HLA-C;...
Rheumatoid arthritis 1.68 2.90e-2 78/93 (83.87%) CTSK;CCL2;MMP1;...
Hepatitis C 1.68 2.86e-2 139/157 (88.54%) CDKN1A;LDLR;MX1;...
Apoptosis 1.67 2.75e-2 126/168 (75%) CTSK;TNFRSF10B;GADD45A;...
Cytokine-cytokine receptor interaction 1.67 2.87e-2 246/295 (83.39%) GDF15;TNFRSF10B;INHBA;...
Kaposi sarcoma-associated herpesvirus infection 1.66 2.88e-2 172/193 (89.12%) CDKN1A;CLEC2B;MICA;...
Measles 1.65 3.13e-2 133/139 (95.68%) MX1;CCND1;CDK4;...
Non-small cell lung cancer 1.64 3.40e-2 70/72 (97.22%) CDKN1A;DDB2;CCND1;...
Melanoma 1.64 3.29e-2 68/72 (94.44%) CDKN1A;DDB2;CCND1;...
Oocyte meiosis -1.66 4.55e-2 90/129 (69.77%) PPP1CB;ADCY2;PPP3CA;...
Proteasome -1.68 3.66e-2 44/46 (95.65%) PSMF1;PSMC1;PSMD9;...
Amyotrophic lateral sclerosis -1.71 2.63e-2 267/364 (73.35%) RAB5A;PSMD8;DCTN4;...
Protein export -1.77 1.51e-2 17/23 (73.91%) SRPRB;SRPRA;SRP72;...
Proximal tubule bicarbonate reclamation -1.80 1.28e-2 21/23 (91.3%) GLUD2;ATP1B3;ATP1A1;...
RNA transport -1.80 1.41e-2 128/186 (68.82%) NUP155;XPO1;EIF2B5;...
Estrogen signaling pathway -1.82 1.45e-2 119/137 (86.86%) MAPK1;GNAI3;PGR;...
Parkinson disease -1.82 1.26e-2 176/249 (70.68%) COX7A2L;SLC25A5;PSMC1;...
Progesterone-mediated oocyte maturation -1.85 1.15e-2 75/100 (75%) PRKACA;CCNB2;MAPK1;...
Ferroptosis -1.86 1.17e-2 36/41 (87.8%) CYBB;HMOX1;ATG7;...
Phenylalanine metabolism -1.87 1.41e-2 14/17 (82.35%) GOT1;AOC2;GLYAT;...
Nitrogen metabolism -1.88 1.76e-2 16/17 (94.12%) CA5A;CA14;GLUD1;...
Prion disease -1.97 1.00e-2 209/273 (76.56%) PSMD8;COX7A2;NDUFA10;...
Spliceosome -2.08 5.02e-3 101/150 (67.33%) LSM6;PRPF38B;HSPA1L;...
Protein processing in endoplasmic reticulum -2.26 0.00e+0 127/171 (74.27%) VCP;MBTPS1;DNAJC1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-673 CVCL_0080 Homo sapiens 10uM 6H
SK-ES-1 CVCL_0627 Homo sapiens 1.11uM - 10uM 24H
Bone marrow
Chronic myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HAP1 CVCL_Y019 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 BRD4 (-) 1 CVCL_SF59 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 CDK4 (-) 1 CVCL_SI36 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 HDAC5 (-) 1 CVCL_SR11 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 ITGA4 (-) 1 CVCL_ST27 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 MAPK8 (-) 1 CVCL_SW99 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 PIK3CA (-) 1 CVCL_TD60 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 PRKACA (-) 1 CVCL_TG70 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 PRKCQ (-) CVCL_TG92 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 RELA (-) 1 CVCL_TI75 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 SRC (-) 1 CVCL_TQ36 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 TP53 (-) 1 CVCL_RJ70 Homo sapiens 0.66uM - 3.33uM 24H
Neuroblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SH-SY5Y CVCL_0019 Homo sapiens 0.04uM - 10uM 24H
Brain
Glioma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GI-1 CVCL_1230 Homo sapiens 1.11uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.04uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.08uM - 10uM 6H, 24H
MDA-MB-468 CVCL_0419 Homo sapiens 1.11uM - 10uM 24H
SK-BR-3 CVCL_0033 Homo sapiens 0.08uM - 10uM 6H, 24H
Breast carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BT-20 CVCL_0178 Homo sapiens 0.08uM - 10uM 6H, 24H
Hs 578T CVCL_0332 Homo sapiens 0.08uM - 10uM 6H, 24H
Breast ductal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
T-47D CVCL_0553 Homo sapiens 1.11uM - 10uM 24H
Normal (Epithelial)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HME1 CVCL_2950 Homo sapiens 0.04uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.04uM - 10uM 6H, 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.04uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CL-34 CVCL_1123 Homo sapiens 10uM 6H
HT-29 CVCL_0320 Homo sapiens 0.04uM - 10uM 6H, 24H
LoVo CVCL_0399 Homo sapiens 10uM 6H
MDST8 CVCL_1400 Homo sapiens 10uM 6H
NCI-H508 CVCL_1561 Homo sapiens 10uM 6H
SNU-1040 CVCL_5001 Homo sapiens 10uM 6H
SNU-407 CVCL_5004 Homo sapiens 1.11uM - 10uM 24H
SNU-C4 CVCL_5008 Homo sapiens 10uM 6H
SNU-C5 CVCL_5009 Homo sapiens 10uM 6H
SW480 CVCL_0546 Homo sapiens 10uM 6H
SW620 CVCL_0547 Homo sapiens 10uM 6H
SW948 CVCL_0550 Homo sapiens 10uM 6H
Colorectal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCT 116 CVCL_0291 Homo sapiens 10uM 6H
HT115 CVCL_1294 Homo sapiens 10uM 6H
RKO CVCL_0504 Homo sapiens 10uM 6H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 1.11uM - 10uM 6H, 24H
HEC-1-A CVCL_0293 Homo sapiens 1.11uM - 10uM 24H
HEC-251 CVCL_2928 Homo sapiens 1.11uM - 10uM 24H
HEC-265 CVCL_2929 Homo sapiens 1.11uM - 10uM 24H
SNG-M CVCL_1707 Homo sapiens 10uM 6H
Endometrial carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHUEM-2 CVCL_1327 Homo sapiens 10uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 0.04uM - 10uM 24H
CJM CVCL_U797 Homo sapiens 1.11uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.04uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.04uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.04uM - 10uM 6H, 24H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 1.11uM 72H
JHH-5 CVCL_1320 Homo sapiens 1.11uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.04uM - 10uM 6H, 24H
A549/Asc-1 CVCL_YA87 Homo sapiens 0.04uM - 10uM 24H
DV-90 CVCL_1184 Homo sapiens 10uM 6H
NCI-H1573 CVCL_1483 Homo sapiens 1.11uM - 10uM 24H
NCI-H838 CVCL_1594 Homo sapiens 1.11uM - 10uM 24H
SK-LU-1 CVCL_0624 Homo sapiens 10uM 6H
Lung adenosquamous carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H596 CVCL_1571 Homo sapiens 10uM 6H
Lung large cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COR-L23 CVCL_1133 Homo sapiens 10uM 6H
T3M-10 CVCL_1729 Homo sapiens 10uM 6H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BEN CVCL_1081 Homo sapiens 1.11uM - 10uM 24H
HCC15 CVCL_1253 Homo sapiens 10uM 6H
HCC95 CVCL_1276 Homo sapiens 1.11uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1299 CVCL_0060 Homo sapiens 10uM 6H
HCC515 CVCL_5134 Homo sapiens 0.04uM - 10uM 6H, 24H
NCI-H2073 CVCL_1523 Homo sapiens 10uM 6H
NCI-H2110 CVCL_1529 Homo sapiens 1.11uM - 10uM 24H
Small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1694 CVCL_1495 Homo sapiens 10uM 6H
NCI-H1836 CVCL_1502 Homo sapiens 10uM 6H
Lymph node
Diffuse large B-cell lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
WSU-DLCL2 CVCL_1787 Homo sapiens 10uM 6H
Muscle
Rhabdomyosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-204 CVCL_0134 Homo sapiens 1.11uM - 10uM 24H
Ovary
Ovarian carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
EFO-27 CVCL_1194 Homo sapiens 10uM 6H
OV7 CVCL_1623 Homo sapiens 10uM 6H
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OVTOKO CVCL_3114 Homo sapiens 1.11uM - 10uM 24H
RMG-I CVCL_1663 Homo sapiens 10uM 6H
Ovarian mucinous cystadenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COV644 CVCL_2011 Homo sapiens 10uM 6H
RMUG-S CVCL_1666 Homo sapiens 10uM 6H
Ovarian undifferentiated carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
TYK-nu CVCL_1774 Homo sapiens 10uM 6H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.04uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.04uM - 10uM 6H, 24H
Acute myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NOMO-1 CVCL_1609 Homo sapiens 10uM 6H
PL-21 CVCL_2161 Homo sapiens 10uM 6H
SKM-1 CVCL_0010 Homo sapiens 10uM 6H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.04uM - 10uM 24H
Pleural effusion
Histiocytic lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-937 CVCL_0007 Homo sapiens 10uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
22Rv1 CVCL_1045 Homo sapiens 1.11uM - 10uM 24H
PC-3 CVCL_0035 Homo sapiens 0.04uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.04uM - 10uM 6H, 24H
IGR-37 CVCL_1303 Homo sapiens 1.11uM - 10uM 24H
Mel-HO CVCL_1402 Homo sapiens 1.11uM - 10uM 24H
SH-4 CVCL_1692 Homo sapiens 1.11uM - 10uM 24H
SK-L CVCL_1699 Homo sapiens 0.04uM - 10uM 24H
SK-MEL-1 CVCL_0523 Homo sapiens 10uM 6H
SK-MEL-28 CVCL_0526 Homo sapiens 10uM 6H
Stomach
Gastric adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
AGS CVCL_0139 Homo sapiens 10uM 6H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.04uM - 10uM 24H
Urinary bladder
Bladder carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BC-3C CVCL_1079 Homo sapiens 1.11uM - 10uM 24H
Bladder transitional cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CAL-29 CVCL_1109 Homo sapiens 1.11uM - 10uM 24H